Cargando…

Treatment with rituximab in idiopathic membranous nephropathy

BACKGROUND: Rituximab represents a valid therapeutic option to induce remission in patients with primary glomerulonephritis. Despite several studies proving its efficacy in improving outcomes in patients with membranous nephropathy (MN), its role in therapeutic protocols is not yet defined. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiorentino, Marco, Tondolo, Francesco, Bruno, Francesca, Infante, Barbara, Grandaliano, Giuseppe, Gesualdo, Loreto, Manno, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Glomerulopathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5162414/ https://www.ncbi.nlm.nih.gov/pubmed/27994855 http://dx.doi.org/10.1093/ckj/sfw091

Ejemplares similares

Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy
por: Jullien, Perrine, et al.
Publicado: (2017)

The size of palatine tonsils cannot be used to decide the indication of tonsillectomy for IgA nephropathy
por: Sato, Mitsuhiro, et al.
Publicado: (2017)

C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome
por: Lloyd, Isaac E., et al.
Publicado: (2016)

MMP2 and MMP9 associate with crescentic glomerulonephritis
por: Phillips, Tessa M., et al.
Publicado: (2017)

Nephrotic syndrome due to minimal change disease secondary to spider bite: clinico-pathological case of a non-described complication of latrodectism
por: Méndez, Gonzalo P., et al.
Publicado: (2017)

B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis
por: Lundberg, Sigrid, et al.
Publicado: (2017)

The efficacy of rituximab in adult frequently relapsing minimal change disease
por: King, Catherine, et al.
Publicado: (2017)

Dense deposit disease: a greatly increased biopsy incidence in India versus the USA
por: Prema, K S Jansi, et al.
Publicado: (2019)

Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy
por: Bharati, Joyita, et al.
Publicado: (2018)

Recurrence of immunoglobulin A nephropathy after kidney transplantation: a narrative review of the incidence, risk factors, pathophysiology and management of immunosuppressive therapy
por: Infante, Barbara, et al.
Publicado: (2020)

Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy
por: Netti, Giuseppe Stefano, et al.
Publicado: (2019)

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial
por: Scolari, Francesco, et al.
Publicado: (2019)

Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: Lu, Huijuan, et al.
Publicado: (2022)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review
por: Jeon, Soo-Jee, et al.
Publicado: (2022)

Retracted: Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Recurrent idiopathic membranous nephropathy in the renal allograft: successful treatment with the anti-CD20 monoclonal antibody rituximab
por: Ladino, Marco, et al.
Publicado: (2009)

Pre-Transplant Expression of CCR-2 in Kidney Transplant Recipients Is Associated With the Development of Delayed Graft Function
por: Pontrelli, Paola, et al.
Publicado: (2022)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience
por: Chen, Ping, et al.
Publicado: (2023)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

Branchio-Oto-Renal Syndrome (BOR) associated with focal glomerulosclerosis in a patient with a novel EYA1 splice site mutation
por: Gigante, Maddalena, et al.
Publicado: (2013)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

On-line hemodiafiltration modulates atherosclerosis signaling in peripheral lymphomonocytes of hemodialysis patients
por: Simone, Simona, et al.
Publicado: (2021)

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal
por: Rojas-Rivera, Jorge Enrique, et al.
Publicado: (2019)

Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
por: Wang, Yao-Wei, et al.
Publicado: (2023)

Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience
por: Katsuno, Takayuki, et al.
Publicado: (2017)

Glomerulonephritis in AKI: From Pathogenesis to Therapeutic Intervention
por: Pesce, Francesco, et al.
Publicado: (2021)

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Emerging Biomarkers in Renal Damage
por: Ditonno, Pasquale, et al.
Publicado: (2014)

A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus–Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study
por: Rojas-Rivera, Jorge, et al.
Publicado: (2015)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Recent advances in molecular mechanisms of acute kidney injury in patients with diabetes mellitus
por: Infante, Barbara, et al.
Publicado: (2023)

Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report
por: Zhang, Fan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sumd0bv6atg2nl540lbfijjt7e